Back

Body mass index as a contributor to the accumulation of lipidic plaque materials in statin-treated type 2 diabetic patients with coronary artery disease: sub-analysis from the OPTIMAL randomized study

2 September 2024 (13:00 - 13:40)
Organised by: Logo
Congress Presentation Part of: Lipids as risk factors among different populations Obesity ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Anthony Salib

Austin Hospital, Melbourne (Australia)

5 More presentations in this session

Presentation thumbnail
The associations of triglyceride glucose and its derived indexes with 10-year cardiovascular disease risk in a Chinese community-based population
Doctor F. Fan (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Lipid changes across menopause status point to increased cardiovascular risk
Doctor S. Moreno (Dallas, US)
Abstract Slides Video
Presentation thumbnail
Clinical Deep Data Accumulation System (CLIDAS) reveals a "Lipid paradox" of hypertriglyceridemia in Japanese patients.
Doctor S. Katsuki (Fukuoka, JP)
Abstract Slides Video
Presentation thumbnail
Patient reported outcomes, control of hypertension and dyslipidemia: results of two epidemiological studies in Romania, conducted during pandemia (Snapshot-1) and post-pandemic (Snapshot-2)
Doctor A. Ciobanu (Bucharest, RO)
Abstract Slides Video
Presentation thumbnail
Trajectories of lipid profile during adolescence and risk of subclinical atherosclerosis in early adulthood: a two-decade population-based study
Doctor F. Esmaeili (Oxford, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Lipids as risk factors among different populations

The Event

Event poster

ESC Congress 2024

2 September 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Different response of plaque regression under achieving LDL-C <1.8 mmol/L in non-obese and obese diabetic patients with coronary artery disease: a sub-analysis from the OPTIMAL randomized study
thumbnail
Congress Presentation
Progressive disease substrate in obese type 2 diabetic patients with coronary artery disease despite achieving HbA1c <7.0%: sub-analysis from the OPTIMAL randomized study
thumbnail
Congress Presentation
Apolipoprotein B and the regression of lipidic plaque in statin-treated type 2 DM patients with coronary artery disease: the pre-specified sub-analysis from the OPTIMAL randomized controlled trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources